Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-153-9 | CAS number: 134-71-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Animal experimental study, minor restrictions in design and/or reporting but otherwise adequate for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 977
Materials and methods
- Objective of study:
- metabolism
- Principles of method if other than guideline:
- Investigations were carried out with radiolabled substance to establish whether difference exist in their metabolic fate in the rabbit, in vivo and in vitro.
- GLP compliance:
- no
Test material
- Reference substance name:
- (R*,S*)-(±)-α-[1-(methylamino)ethyl]benzyl alcohol hydrochloride
- EC Number:
- 205-153-9
- EC Name:
- (R*,S*)-(±)-α-[1-(methylamino)ethyl]benzyl alcohol hydrochloride
- Cas Number:
- 134-71-4
- Molecular formula:
- C10 H15 N O .Cl H
- IUPAC Name:
- (1-hydroxy-1-phenylpropan-2-yl)(methyl)azanium chloride
- Details on test material:
- - Name of test material (as cited in article): D(-)ephedrine and L(+)-ephedrine
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- carbinol-14C
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Weight at study initiation: 1.6 - 2.5 kg
- Fasting period before study: not performed
- Housing: metabolic cages
- Individual metabolism cages: no, per 2 animals
- Diet: ad libitum
- Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature: room temperature
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- Animals received a combination of (±)-[cabinol-14C]ephedrine diluted with nonradioactive (±)-ephedrine (1:1.5).
- Duration and frequency of treatment / exposure:
- Single injection
Doses / concentrations
- Remarks:
- Doses / Concentrations:
3 - 5 µCi (= 3 mg/kg bw)
- No. of animals per sex per dose / concentration:
- 6
- Details on study design:
- IN VITRO STUDY:
After the animals were killed by a blow on the head, the liver was excised and transferred. The microsomes were extracted and used for in vitro incubation. Incubation mixtures consisted of 5 mg of microsomal protein, 2.5 μmol of substrate, a NADPH-generating system and 150 μmol of Tris-HCI buffer, pH 7.4, in a final volume of 3.0 mL. After the addition of L(+)- or D(-)-ephedrine (0.4-0.8 µCi/mg), all flasks were transferred from ice to a Dubnoff metabolic shaker and incubated in air at 37°C with shaking (90 oscillations/min) for 15, 30, and 60 min. Aliquots of each incubation flask were either freeze-dried or transferred to scintillation vials for the quantitation of radioactivity. - Details on dosing and sampling:
- METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine, faeces, tissues
- Time and frequency of sampling: urine and faeces 24 hr-intervals for 6 days
- From how many animals: combined from 2 animals
- Method type(s) for identification: Liquid scintillation counting
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on excretion:
- IN VIVO STUDY
From both isomers, > 80% of the total 14C was excreted within 48 hr after dosing; the majority of 14C excretion (71-91%) occurred within 24 hr. Small amounts of radioactivity were detected in the urine even after 6 days. From the data presented, it was also observed that the urinary elimination of radioactivity by rabbits dosed with D(-)-ephedrine was slower than by those given L(+)-ephedrine. Although not presented, elimination of 14C in feces did not appear to be an important route; < 3% of the total 14C of the ephedrine isomers were recovered in feces within the first 48 hr.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- IN VITRO STUDY
Both isomers of ephedrine were extensively metabolized after a 1-hr incubation. D(-)-ephedrine was metabolized to a greater degree and the amounts of benzoic acid and norephedrine formed from this isomer exceeded those formed from L(+)-ephedrine. Quantitation of the metabolites by inverse isotope-dilution analysis and two-dimensional chromatography revealed that nearly all of the 14C (91-98%) was present as benzoic acid, ephedrine, and norephedrine. Unchanged ephedrine, norephedrine, 1-phenyl-1,2-propanediol, and benzoic acid represented the majority of radioactivity (90-95%) present at the various incubation times. It is clear that a) D(-)-ephedrine was more rapidly metabolized than the L(+)-isomer, b) comparable rates of nor- ephedrine and 1-phenyl-1,2-propanediol formation were observed with both isomers, and c) the rate of benzoic acid formation from D(-)-ephedrine was about three times greater than that from L(+)-ephedrine over the entire incubation period. Further, the data showed that norephedrine was the predominant metabolite formed from both ephedrine isomers and that oxidative deamination of the side chain to form benzoic acid and 1-phenyl-1,2-propancdiol constituted a major route of biotransformation for both isomers in rabbit liver microsomes.
IN VIVO STUDY
Little unchanged ephedrine, norephedrine, or 1-hydroxy-1-phenyl-2- propanone was present in the urine of rabbits dosed with either ephedrine isomer. In each case, greater amounts of these 14C-metabolites were found in the urine of animals given L(+)-ephedrine. The major 14C-metabolites of both isomers were hippuric and benzoic acids. The total amount of hippuric acid excreted from rabbits dosed with D(-)-ephedrine was greater than that from L(+)-ephedrine (30% vs. 16%). Greater amounts of hippuric acid and lesser amounts of benzoic acid were found in urine of rabbits dosed with D(-)-ephedrine. Hippuric acid accounted for about 21% and 35% of the 24-hr 14C excretion for L(+)- and D(-)-ephedrine, respectively. More 1-phenyl-1,2-propanediol, either free or conjugated, was present in the urine of rabbits receiving L(+)-ephedrine.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
These experiments indicate that the major pathway for the biotransformation of D(-)-ephedrine and L(+)-ephedrine involves N-demethylation and oxidative deamination of the side chain. - Executive summary:
Investigations were carried out with radiolabeled D(-)-ephedrine and L(+)-ephedrine to establish whether differences exist in their metabolic fate in the rabbit, in vivo and in vitro.In liver microsomal preparations, D(-)-ephedrine was metabolized at a faster rate than L(+)-ephedrine, benzoic acid was formed from D(-)-ephedrine at a rate about three times greater than from the L(+)-isomer, and the relative amounts of norephedrine and 1-phenyl-1,2-propranediol formed from both ephedrine isomers were nearly identical throughout the entire incubation period. In vivo, both ephedrine isomers were extensively metabolized and the majority of total radioactivity (71-91%) was excreted within 24 hr. A greater 14C-excretion rate was observed for L(+)-ephedrine. From an analysis of 0- to 24-hr urine, it was found that 47-50% of the urinary 14C was attributable to acidic metabolites (hippuric acid and benzoic acid) from L(+)- and D(-)-ephedrine, from 4 to 16% of the total 14C obtained with both isomers was accountable as 1-phenyl-1,2-propanediol, either free or as a glucuronide conjugate, no appreciable quantities of sulfate or glucuronide conjugates of p-hydroxylated metabolites of ephedrine or norephedrine was detectable, and small amounts (<4% of metabolites corresponding to unchanged ephedrine, norephedrine, or 1-hydroxy-l-phenyl-2- propanone were found in urine of animals given either isomer. These experiments indicate that the major pathway for the biotransformation of D(-)-ephedrine and L(+)-ephedrine involves N-demethylation and oxidative deamination of the side chain.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.